Novartis Loses Glivec Patent Fight In India
A patent tribunal in India has rejected Novartis AG's bid to secure a patent for its cancer drug Glivec, marking the latest chapter in the Swiss drugmaker's long-running battle with Indian...To view the full article, register now.
Already a subscriber? Click here to view full article